Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo

Tel:  +47 21 07 81 60

New search    Hide text from Guidelines


Inhaled antiinfectives are classified in ATC group J - Antiinfectives for systemic use.


It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs. This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages. It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available. Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).
For some substances, the labelling of the strength of identical inhalation products may differ between countries. In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling. Delivered dose will usually be lower than metered dose. This is important to take into considerations when linking DDD information to the products in the different countries.
The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value. The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.

R03AC Selective beta-2-adrenoreceptor agonists

The DDDs are mainly based on the treatment of asthma.
The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.
The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).

    ATC code  Name  DDD  U Adm.R Note
    R03AC02 salbutamol 0.8 mg Inhal.aerosol 
    0.8 mg Inhal.powder 
    10 mg Inhal.solution 
    R03AC03 terbutaline mg Inhal.aerosol 
    mg Inhal.powder 
    20 mg Inhal.solution 
    R03AC04 fenoterol 0.6 mg Inhal.aerosol 
    0.6 mg Inhal.powder 
    mg Inhal.solution 
    R03AC05 rimiterol 1.6 mg Inhal.aerosol 
    R03AC06 hexoprenaline 1.5 mg Inhal.aerosol 
    R03AC07 isoetarine    
    R03AC08 pirbuterol 1.2 mg Inhal.aerosol 
    R03AC09 tretoquinol    
    R03AC10 carbuterol    
    R03AC11 tulobuterol 1.6 mg Inhal.aerosol 
    R03AC12 salmeterol 0.1 mg Inhal.aerosol 
    0.1 mg Inhal.powder 
    R03AC13 formoterol 24 mcg Inhal.aerosol 
    24 mcg Inhal.powder 
    R03AC14 clenbuterol    
    R03AC15 reproterol    
    R03AC16 procaterol 60 mcg Inhal.aerosol 
    R03AC17 bitolterol    
    R03AC18 indacaterol 0.15 mg Inhal.powder 
    R03AC19 olodaterol mcg Inhal.solution 

List of abbreviations

Last updated: 2021-12-14